Skip to main content

Advertisement

Table 4 Predictors of reduced total, cortical, and trabecular bone mineral density in patients with nonradiographic axial spondyloarthritis

From: Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis

  Total BMD Ct. BMD Trab. BMD
β T p β T p β T p
Model 1
 Age 0.006 0.068 0.946 −0.038 −0.449 0.654 −0.073 − 0.952 0.342
 Sex (male vs. female) − 0.143 −1.730 0.086 0.285 3.523 0.001 −0.466 −6.324 <  0.001
 BMI 0.079 0.915 0.362 −0.004 − 0.042 0.966 0.083 1.080 0.282
 Smoking (yes/no) 0.118 1.415 0.159 −0.041 − 0.505 0.615 0.103 1.378 0.171
 Intercept 11.570 <  0.001 29.784 <  0.001 12.765 <  0.001
R2 adjusted 0.016 0.059 0.219
Model 2
 Age −0.109 −0.913 0.364 −0.094 − 0.858 0.393 − 0.151 −1.498 0.138
 Sex −0.095 −0.847 0.399 0.300 2.937 0.004 −0.420 −4.448 <  0.001
 BMI 0.115 1.036 0.303 0.017 0.164 0.870 0.159 1.689 0.095
 Remission −0.017 −0.150 0.881 0.015 0.147 0.883 0.048 0.512 0.610
 Disease duration 0.157 1.241 0.218 −0.169 −1.460 0.148 0.280 2.625 0.010
 Anti-TNF −0.094 −0.776 0.440 −0.131 −1.176 0.243 −0.160 −1.557 0.123
 GC (yes/no) −0.132 −1.131 0.261 0.109 1.023 0.309 −0.205 −2.078 0.041
 HLA-B27 positivity −0.027 −0.254 0.800 0.002 0.020 0.984 0.027 0.304 0.762
 Peripheral arthritis 0.011 0.095 0.924 −0.041 −0.404 0.687 −0.093 −0.987 0.327
 Intercept 8.522 <  0.001 23.225 <  0.001 9.761 <  0.001
R2 adjusted −0.038 0.130 0.258
  1. Abbreviations: BMD Bone mineral density, Ct. BMD Cortical bone mineral density, Trab. BMD Trabecular bone mineral density, axSpA axial spondyloarthritis, BMI Body mass index, Anti-TNF Current treatment with anti-tumor necrosis factor α inhibitor, GC History of glucocorticoid treatment with ≥ 5 mg prednisolone equivalent daily for > 3 mo
  2. Remission status according to Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP, inactive disease ASDAS-CRP < 1.3)
  3. Bold indicates significant differences (p < 0.05)